Moderna Inc
As on 23 May, 2025 | 01:29 IST
| Open | 25.75 |
| Previous Close | 25.81 |
| Beta | -0.01 |
| High | 28.07 |
| Low | 25.22 |
| TTM EPS See historical trend | -8.73(+44.29% YoY) |
| 52 Week High | 169.92 |
| 52 Week Low | 23.24 |
| TTM PE See historical trend | -3.06(Low PE) |
| Mkt. Cap ($ Billion) | 10.23 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 26.35 |
| 10 | 25.49 |
| 20 | 26.06 |
| 50 | 28.09 |
| 100 | 32.43 |
| 200 | 47.59 |
Returns
| 1 Week | 13.00% | |
| 1 Month | 3.76% | |
| 3 Months | -24.76% | |
| YTD | -35.67% | |
| 1 Year | -83.61% | |
| 3 Years | -80.38% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Amgen | 330.11 | -3.37 | 177.44 | 15.09 | 21.87 | 3.33 | 346.38/260.71 | 2.76 | Very Bearish |
| Gilead Sciences | 120.73 | -2.91 | 150.42 | 14.73 | 8.19 | 2.83 | 128.68/88.59 | -0.41 | Neutral |
| Vertex Pharmaceuticals | 469.68 | -2.99 | 121.35 | 27.06 | 17.36 | -- | 519.68/362.97 | 6.39 | Very Bearish |
| Regeneron Pharmaceuticals | 801.31 | -1.35 | 87.92 | 17.80 | 45.01 | 0.47 | 816.99/476.79 | 13.96 | Very Bearish |
| Biogen | 184.51 | -1.28 | 18.41 | 7.99 | 15.82 | -- | 237.98/110.27 | 6.28 | Bullish |
Market news
- Dow closes higher on first day of 2026, still no Santa Claus rallyJanuary 3, 2026 8:19 AM
- Wall Street ends close to all-time highs in light, post-holiday sessionDecember 27, 2025 8:09 AM
- Dow, S&P 500 close at record highs as Santa rally startsDecember 25, 2025 8:04 AM
- Stocks rise with tech boost, yen weakens after Japan rate hikeDecember 20, 2025 12:20 PM
About the company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.